-

TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update

CONFERENCE CALL TO BE HELD MONDAY, NOVEMBER 9, 2026, AT 8:30 AM ET

NEW YORK--(BUSINESS WIRE)--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 9, 2026, at 8:30 AM ET to discuss results for the third quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT TG THERAPEUTICS

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

Contacts

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

TG Therapeutics, Inc.

NASDAQ:TGTX

Release Versions
$Cashtags

Contacts

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

Social Media Profiles
More News From TG Therapeutics, Inc.

TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™

NEW YORK--(BUSINESS WIRE)--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 5 on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 32nd year.The Company’s growth between fiscal years 2022 to 2025 was fueled by BRIUMVI® revenues, which was approved to treat adult individuals with relapsing forms of multiple sclerosis in December of 2022...

TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

NEW YORK--(BUSINESS WIRE)--TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four ye...

TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026

NEW YORK--(BUSINESS WIRE)--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company’s Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with progressive multiple sclerosis (MS). The data represent the first reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS and were presented in a late-breaking oral sess...
Back to Newsroom